News coverage about AMAG Pharmaceuticals (NASDAQ:AMAG) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. AMAG Pharmaceuticals earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 45.3227192933392 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern’s rankings:
- Remarkable stocks: Altaba Inc., (NASDAQ: AABA), AMAG Pharmaceuticals, Inc., (NASDAQ: AMAG), The AES … – Stocks In The News (press release) (tradingnewsnow.com)
- AMAG Pharmaceuticals, Inc. (AMAG) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
- Brokerages Expect AMAG Pharmaceuticals, Inc. (AMAG) Will Announce Quarterly Sales of $163.39 Million (americanbankingnews.com)
- AMAG Pharmaceuticals, Inc. (AMAG) Expected to Post Earnings of $0.10 Per Share (americanbankingnews.com)
- ETFs with exposure to AMAG Pharmaceuticals, Inc. : November 9, 2017 (finance.yahoo.com)
Shares of AMAG Pharmaceuticals (NASDAQ AMAG) opened at $13.65 on Wednesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. AMAG Pharmaceuticals has a 52 week low of $11.93 and a 52 week high of $36.83.
Several equities research analysts have issued reports on the stock. Piper Jaffray Companies assumed coverage on shares of AMAG Pharmaceuticals in a research note on Monday, October 23rd. They set a “neutral” rating and a $18.00 target price on the stock. Zacks Investment Research cut shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 26th. BidaskClub lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Cowen and Company reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Thursday, August 10th. Finally, Janney Montgomery Scott reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Tuesday, October 17th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and three have assigned a buy rating to the stock. AMAG Pharmaceuticals has an average rating of “Hold” and a consensus target price of $24.00.
COPYRIGHT VIOLATION NOTICE: “AMAG Pharmaceuticals (NASDAQ:AMAG) Given Daily Media Impact Score of 0.13” was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://weekherald.com/2017/11/15/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-amag-pharmaceuticals-amag-share-price.html.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.